Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis

Vaccine

Volumn 32, Issue 11, 2014, Pages 1287-1295

  Fernandes, Consuelo Barreto ^a   Junior, Jairo Torres Magalhães ^a   De Jesus, Clauceane ^a   Da Silva Souza, Bárbara Maria Paraná ^a   Larangeira, Daniela Farias ^a   Fraga, Deborah Bittencourt Mothé ^a,b   Tavares Veras, Patricia Sampaio ^b   Barrouin Melo, Stella Maria ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Canine immunization; Leishmania infantum; Leishmune and Leish Tec ; Lutzomyia longipalpis; Reactogenicity; Xenodiagnosis

Indexed keywords

CANINE IMMUNIZATION; LEISHMANIA INFANTUM; LEISHMUNE(®) AND LEISH-TEC(®); LUTZOMYIA LONGIPALPIS; REACTOGENICITY; XENODIAGNOSIS;

ANIMALS; ANTIBODIES, PROTOZOAN; BRAZIL; DOG DISEASES; DOGS; FEMALE; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MALE; PROSPECTIVE STUDIES; VACCINATION; XENODIAGNOSIS;

EID: 84893914715     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.046     Document Type: Article

References (59)

1. WHO.World Health Organization (accessed: 07.01.14). http://www.who.int/leishmaniasis/burden/magnitude/burden_magnitude/en/index.html.
2. WHO Report on neglected tropical diseases 2012, World Health Organization, http://www.who.int/neglected_diseases/2012/report/en/index.htme (accessed: 15.09.12).
3. Kuhls K., Alam M.Z., Cupolillo E., Ferreira G.E.M., Mauricio I.L., Oddone R., et al. Comparative microsatellite typing of New World Leishmania infantum reveals low heterogeneity among populations and its recent Old World origin. PLoS Negl Trop Dis 2011, 5:1-16.
4. Ministério da Saúde[[nl]]Ministry of Health of Brazil Portal da saúde SUS-Sinan/SVS/MS 2012, Ministério da Saúde[[nl]]Ministry of Health of Brazil, Brazil, http://portal.saude.gov.br/portal/arquivos/pdf/2012_11_casos_de_lv_entre_1990_e_2011_final.pdf (accessed: 14.12.12).
5. Maia-Elkhoury A.N., Alves W.A., Sousa-Gomes M.L., Sena J.M., Luna E.A. Visceral leishmaniasis in Brazil: trends and challenges. Cad Saud Publica 2008, 24:2941-2947.
6. Courtenay O., Quinnell R.J., Garcez L.M., Shaw J.J., Dye C. Infectiousness of a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 2002, 186:1314-1320.
7. Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 1996, 55:125-130.
8. Alvar J., Canavate C., Molina R., Moreno J., Nieto J. Canine leishmaniasis. Adv Parasitol 2004, 57:1-88.
9. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., Palatnik M., et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 2001, 19:1068-1078.
10. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., de Souza E.P., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante). Vaccine 2002, 20:3277-3284.
11. ® vaccine against canine visceral leishmaniasis in Brazil. Vaccine 2007, 25:2180-2186.
12. Coelho E.A., Tavares C.A., Carvalho F.A., Chaves K.F., Teixeira K.N., Rodrigues R.C., et al. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 2003, 71:3988-3994.
13. Zanin F.H., Coelho E.A., Tavares C.A., Marques-Silva E.A., Silva-Costa M.M., Rezende S.A., et al. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Microb Infect 2007, 9:1070-1077.
14. Fernandes A.P., Costa M.M.S., Coelho E.A.F., Michalick M.S.M., Freitas E., Melo M.N., et al. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008, 26:5888-5895.
15. Ministério da Saúde, Ministério da Agricultura, Pecuária e Abastecimento, Instrução normativa interministerial no. 31, 2009, M.A.P.A.; Brasil, Nota de Esclarecimento sobre as Vacinas Antileishmaniose Visceral Canina registradas no M.A.P.A., (accessed: 07.01.14). http://www.agricultura.gov.br/arq_editor/file/Aniamal/Registros_Atorizacoes/Produtos_veterinarios/Comunicacoes_e_instrucoes_tecnicas/Nota_de_esclarecimento_sobre_a_vacina.pdf.
16. Ministério da Saúde. Secretaria de Vigilância em Saúde, Brasil. Nota técnica vacina anti-leishmaniose visceral canina Leishmune®. (accessed: 15.09.11). http://portal.saude.gov.br/portal/arquivos/pdf/leishimune_nota_tecnica.pdf.
17. Ministério da Agricultura, Pecuária e Abastecimento, Brasil. Instrução Normativa Interministerial n̊ 31. Regulamento Técnico para Pesquisa, Desenvolvimento, Produção, Avaliação, Registro e Renovação de Licenças, Comercialização e Uso de Vacina Contra a Leishmaniose Visceral Canina. (accessed: 06.06. 11). http://sistemasweb.agricultura.gov.br/sislegis/action/detalhaAto.do%3Fmethod=visualizarAtoPortalMapa%26chave=815005048.
18. ®) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 2006, 24:2423-2431.
19. Barboza D.C.P.M., Gomes Neto C.M.B., Leal D.C., Bittencourt D.V.V., Carneiro A.J.B., Souza B.M.P.S., Oliveira L.S., Julião F.S., Souza V.M.M., Franke C.R. Cohort study in areas at risk for canine visceral leishmaniasis in municipalities of the metropolitan region of Salvador, Bahia. Braz Rev Bras Saude Prod Anim 2006, 7:152-163.
20. Bastos L.A., Bordoni M.G., Solcá M.S., Silva M.M.N., Pereira G.C., Santos W.L.C., Veras P.S.T., Bavia M.E., Fraga D.B.M. Distribuição da leishmaniose visceral canina no município de Camaçari, Bahia. XXVII Reunião de Pesquisa Aplicada em Doença de Chagas e XV Reunião de Pesquisa Aplicada em Leishmanioses 2011, Universidade Federal do Triângulo Mineiro, Uberaba.
21. IBGE. Instituto Brasileiro de Geografia e Estatística. (acessed: 07.01.14). http://cidades.ibge.gov.br/xtras/uf.php%3Flang=%26coduf=29%26search=bahia.
22. Presidência da República do Brasil. LEI 11.794/2008 (LEI ORDINÁRIA) 08.10.2008. Disponível em: (accessed: 07.01.14). http://www.planalto.gov.br/ccivil_03/_ato2007-2010/2008/lei/l11794.htm.
23. Fort Dodge Saúde Animal Ltda[[nl]]Fort Dodge Animal Health Manual técnico vacina Leishmune 2004, 51. Fort Dodge Saúde Animal Ltda[[nl]]Fort Dodge Animal Health, Fort Dodge.
24. Hertape Callier Saúde Animal Ltda[[nl]]Hertape Callier Animal Health Manual técnico vacina Leish-Tec 2008, 76. Hertape Callier Saúde Animal Ltda[[nl]]Hertape Callier Animal Health, Hertape Callier.
25. Solano-Gallego L., Koutinas A., Miro G., Cardoso L., Pennisi M.G., Ferrer L., et al. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet Parasitol 2009, 165:1-18.
26. Barrouin-Melo S.M., Larangeira D.F., de Andrade Filho F.A., Trigo J., Juliao F.S., Franke C.R., et al. Can spleen aspirations be safely used for the parasitological diagnosis of canine visceral leishmaniosis?. A study on asymptomatic and polysymptomatic animals. Vet J 2006, 171:331-339.
27. Paranhos-Silva M., Freitas L.A.R., dos-Santos W.L.C., Grimaldi L., Pontes-de-Carvalho L., Oliveira-dos-Santos A.J. A cross-sectional serodiagnostic survey of canine leishmaniasis due to Leishmania chagasi. Am J Trop Med Hyg 1996, 51:39-44.
28. Zwirner N.W. ELISA. Imunología e imunoquímica 1996, 798-820. Editorial Médica Panamericana, Buenos Aires, 976 p. 5th ed. R.A. Margni (Ed.).
29. Oliveira-Freitas E., Casas C.P., Borja-Cabrera G.P., Santos F.N., Nico D., Souza L.O.P., et al. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 2006, 24:3909-3920.
30. Kensil C.R., Patel U., Lennick M., Marciani D.J. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 1991, 146:431-437.
31. Santos W.R., de Lima V.M.F., de Souza E.P., Bernardo R.R., Palatnik M., Palatinik-de-Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 2002, 21:30-43.
32. Moore G.E., Hogenesch H. Adverse vaccinal events in dogs and cats. Vet Clin N Am Small Anim Pract 2010, 40:393-407.
33. ® vaccinated and visceral leishmaniasis infected dogs from an endemic area. Vet Parasitol 2010, 173:55-63.
34. Lachaud L., Chabbert E., Dubessay P., Dereure J., Lamothe J., Dedet J.P., et al. Value of two PCR methods for the diagnosis of canine visceral leishmaniasis and the detection of asymptomatic carriers. Parasitology 2002, 125:197-207.
35. Dye C., Killick-Kendrick R., Vitutia M., Walton R., Killick-Kendrick M., Harith A., et al. Epidemiology of canine leishmaniasis: prevalence, incidence and basic reproduction number calculated from a cross-sectional serological survey on the island of Gozo, Malta. Parasitology 1992, 105:35-44.
36. Verçosa B., Lemos C., Mendonça I., Silva S., de Carvalho S., Goto H., et al. Transmission potential, skin inflammatory response, and parasitism of symptomatic and asymptomatic dogs with visceral leishmaniasis. BMC Vet Res 2008, 4:45.
37. ®. Vet Parasitol 2011, 181:153-159.
38. Borja-Cabrera G.P., da Silva V.O., da Costa R.T., Reis A.B., Mayrink W., Genaro O., et al. The fucose-manose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil. Am J Trop Med Hyg 1999, 61:296-301.
39. Mendes C.O., de Souza E.P., Borja-Cabrera G.P., Batista L.M.M., dos Santos M.A., Parra L.E., et al. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis. Vaccine 2003, 21:2589-2597.
40. ®). Vet Parasitol 2013, 197:649-652.
41. Bordoni M.G., Merelles S.L., Solcá M.S., Borja L.S., Santos L.S., Santos L.C.S., Leite B.M.M., Guedes Junior J.C.O., Pereira G.C., Bavia M.E., Santos W.L.C., Veras P.S.T., Fraga D.B.M. Identification of risk factors associated to canine visceral leishmaniasis in an endemic area of Bahia. XVIII international congress for tropical medicine and malaria and XLVIII congress of the Brazilian Society for Tropical Medicine, vol. 1 2012, 452-453.
42. Solano-Gallego L., Riera C., Roura X., Iniesta L., Gallego M., Valladares J.E., et al. Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Vet Parasitol 2001, 96:265-276.
43. Quinnell R.J., Courtenay O., Garcez L.M., Kaye P.M., Shaw M.A., Dye C., et al. IgG subclass responses in a longitudinal study of canine visceral leishmaniasis. Vet Immunol Immunopathol 2003, 91:161-168.
44. da Costa-Val A.P., Cavalcanti R.R., de Figueiredo G.N., Marques M.M.S., Alexander B., Williams P., et al. Canine visceral leishmaniasis: relationships between clinical status, humoral immune response, haematology and Lutzomyia (Lutzomyia) longipalpis infectivity. Vet J 2007, 174:636-643.
45. Travi B.L., Osorio E.Y., Saldarriaga O.A., Cadena H., Tabares C.J., Peniche A., et al. Clinical, parasitologic, and immunologic evolution in dogs experimentally infected with sand fly-derived Leishmania chagasi promastigotes. Am J Trop Med Hyg 2009, 81:994-1003.
46. Boggiatto P.M., Ramer-Tait A.E., Metz K., Kramer E.E., Gibson-Corley K., Mullin K., et al. Immunologic indicators of clinical progression during canine Leishmania infantum infection. Clin Vaccine Immunol 2010, 17:267-273.
47. Carson C., Quinnell R.J., Day M.J., Courtenay O. Comparison of monoclonal and polyclonal antibodies for the detection of canine IgG1 and IgG2, and associations with infection outcome in Leishmania infantum naturally infected dogs. Vet Immunol Immunopathol 2010, 133:264-268.
48. Barrouin-Melo S.M., Larangeira D.F., Trigo J., Aguiar P.H., dos Santos W.L.C., Pontes-de-Carvalho L. Comparison between splenic and lymph node aspirations as sampling methods for the parasitological detection of Leishmania chagasi infection in dogs. Mem Inst Oswaldo Cruz 2004, 99:195-197.
49. Madeira M., Schubach A., Schubach T., Pereira S., Figueiredo F., Baptista C., et al. Post mortem parasitological evaluation of dogs seroreactive for Leishmania from Rio de Janeiro. Braz Vet Parasitol 2006, 138:366-367.
50. Michalsky E.M., Rocha M.F., da Rocha Lima A.C., França-Silva J.C., Pires M.Q., Oliveira F.S., et al. Infectivity of seropositive dogs, showing different clinical forms of leishmaniasis, to Lutzomyia longipalpis phlebotomine sand flies. Vet Parasitol 2007, 147:67-76.
51. Maia C., Ramada J., Cristovão J.M., Goncalves L., Campino L. Diagnosis of canine leishmaniasis: conventional and molecular techniques using different tissues. Vet J 2009, 179:142-144.
52. Sundar S., Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002, 9:951-958.
53. Sanchez M.A., Diaz N.L., Zerpa O., Negron E., Convit J., Tapia F.J. Organ-specific immunity in canine visceral leishmaniasis: analysis of symptomatic and asymptomatic dogs naturally infected with Leishmania chagasi. Am J Trop Med Hyg 2004, 70:618-624.
54. Berrahal F., Mary C., Roze M., Berenger A., Escoffier K., Lamouroux D., et al. Canine leishmaniasis: identification of asymptomatic carriers by polymerase chain reaction and immunoblotting. Am J Trop Med Hyg 1996, 55:273-277.
55. Reis A.B., Teixeira-Carvalho A., Vale A.M., Marques M.J., Giunchetti R.C., Mayrink W., et al. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol 2006, 112:102-116.
56. Teixeira-Neto R.G., Giunchetti R.C., Carneiro C.M., Vitor R.W.A., Coura-Vital W., Quaresma P.F., et al. Relationship of Leishmania-specific IgG levels and IgG avidity with parasite density and clinical signs in canine leishmaniasis. Vet Parasitol 2010, 169:248-257. [57].
57. Macedo B.M., Bordoni M., Merelles S.L., Solcá M.S., Borja L.S., Santos L.C.S., Guedes J.C.O., Pereira G.C., Dos-Santos W.L.C., Almeida M.C.C., Veras P.S.T., Fraga D.B.M. Identification of clinical predictors signs for canine visceral leishmaniasis. Worldleish 5-fifth world congress on leishmaniasis, vol. 1 2013, 526. Abstract Book.
58. ® vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 2005, 23:4805-4810.
59. Andrade P.P., Reis A.B., Gontijo F.M.C., Braga B.L., Rocha R.D.R., Araujo M.S.S., et al. Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs. Vet Immunol Immunopathol 2007, 116:85-87.